Spectrum Pharmaceutecals Inc (SPPI)

[1sdestiny]

Cohort 3 was first line egfr. I did miss the lower bound slightly. It may be that the BID dosing could do better. Too bad tekada
Already has an approval on a drug in that indication for sec line. It’s possible pozi does better, but idk.

Good luck. These results are good. Looking forward to the rolontis bla and start of pozi confirmation study and fast track for first line her 2.